But so far, the company is striking out in its attempts to broaden its label. On Thursday, BMS revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely ...

Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts. Bristol Myers ...

After hours: March 12 at 7:51:23 PM EDT Loading Chart for BMY ...